This is an open lable, pilot study in which the investigator will research the effect of two
FDA approved drugs, Mirabegron and Pioglitazone on fat tissue.
Pioglitazone is drug approved by the FDA for the treatment of diabetes and Mirabegron is a
drug that is approved by the FDA for the treatment of overactive bladder. These drugs are not
approved by the FDA for the purposes being studied in this research. Therefore, the way in
which the investigator intends to use them in this study are considered investigational.
Phase:
Early Phase 1
Details
Lead Sponsor:
Philip Kern
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)